FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count
Executive Summary
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved
You may also be interested in...
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
FDA's second-half surge in approvals made 2008 the agency's best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
FDA's second-half surge in approvals made 2008 the agency's best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation